The case for & against
Bull & Bear analysis
Bullish
Argenx SE (NASDAQ: ARGX) is a leading biopharmaceutical company focused on developing and commercializing innovative therapies for patients with severe autoimmune diseases. Its flagship product, VivGuard, has established strong market presence in treating Myasthenia Gravis (MG) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). With a commitment to expanding its immunology pipeline and leveraging its proprietary technology, Argenx is positioned favorably within the therapeutics landscape, capitalizing on high unmet clinical needs and evolving patient preferences.
Bull says
- ↑Q2’26 VivGuard net sales $1.5B, +60% YoY adoption in MG/CIDP
- ↑PDUFA May 10, 2026 for seronegative MG could expand addressable market by ~11K patients
- ↑Cash reserves $5.2B (↑$744M YTD) fund R&D and commercial expansion
- ↑Pre-filled syringe drives >50% new VivGuard patient adoption
- ↑Strong growth, revision, profitability and momentum factors, low volatility
- ↑Two registrational readouts before year-end support goal of 10 labeled indications
Bear says
- ↓Q2’26 operating expenses hit $1B, pressuring profit margins
- ↓Earnings yield and book-to-price metrics suggest valuation risk
- ↓New entrants like Ablizna heighten pricing and share pressures
- ↓International rollouts face reimbursement delays
- ↓Heavy reliance on VivGuard revenue; trial failures could derail growth
- ↓Leverage concerns and elevated short interest highlight financial risk
Investment themes with ARGX
Demographics Elective Health + Family Care↓ -0.20%
Health services for families and elective treatments
HQY · DOCS · PRVA
Earnings Call · Q2 2025 · Mgmt. Guidance
Updated 08-08-2026neutral
Transcript signals
Bull points
- Thank you for the question on ITP. So the launch in Japan for ITP is actually going well. And what we find exciting is to see that in the real world, the clinical data are actually perfectly met. So we see about a 50% response rate. The drug is landing first in, you know, the last line of ITP patients after they fail steroids, IVIG, and TPO's. So very refractory patient population and still a very nice 50% response rate. And if patients respond, just like in the similar in the clinical trial, they respond very quickly. And the safety profile of the product is also differentiating. I mean, physicians badly need a fast acting safe drug. So I think the drug is landing very well. Uptake is nice. And I think we will be gradually moving our way up in the treatment paradigm.
- this quarter, cash flow increased to almost half a billion for the six month period, which indicates a strong financial position for the company moving forward.
- Hytrulo is driving the majority of the growth for VivGuard, and as you rightly called out, 50% of pre-filled syringe patients are new to VivGuard. So our strategy with bringing these innovations to market in both MG and CIDP is that we're looking to expand the market and improve our differentiation in increasingly competitive markets. And that's exactly what we're seeing the pre-filled syringes delivering is that market growth, market expansion and product growth. So you can expect that to continue, I would say, through the end of the year.
Bear points
- very early on the launch curve
- the bulk of the increase in gross to net is now behind us, suggesting that future increases will be smaller and may reflect the product mix.
- increases in gross to net, but it will be smaller increases driven by the product mix, indicating a cautious outlook on revenue growth.
Read full transcript analysis ›